Orlistat

• CAT Number: A000657
• CAS Number: 96829-58-2
• Molecular Formula: C₂₉H₅₃NO₅
• Molecular Weight: 495.73
• Purity: ≥95%
• Target: lipase inhibitor
• Storage: -20°C
• InChI: InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
• InChIKey: AHLBNYSZXLDEJQ-FWEHEUNISA-N
• SMILES: CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O

Orlistat (CAT: A000657) is a pharmaceutical compound used to manage obesity. It functions as a lipase inhibitor, which means it reduces the absorption of dietary fats in the digestive system. Orlistat is commonly prescribed as a weight-loss medication to help individuals who are overweight or obese lose excess body fat. It works by blocking the enzymes that break down fats in the intestine, thereby reducing the number of calories absorbed from dietary fat.

Reference

1: Solomon LR, Nixon AC, Ogden L, Nair B. Orlistat-induced oxalate nephropathy:
an under-recognised cause of chronic kidney disease. BMJ Case Rep. 2017 Nov
12;2017. pii: bcr-2016-218623. doi: 10.1136/bcr-2016-218623. PubMed PMID:
29133578.

2: Sokolowska E, Presler M, Goyke E, Milczarek R, Swierczynski J, Sledzinski T.
Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer
Cells (PANC-1). Anticancer Res. 2017 Nov;37(11):6321-6327. PubMed PMID: 29061815.

3: Sun S, Jin M, Zhou X, Ni J, Jin X, Liu H, Wang Y. The Application of
Quantitative 1H-NMR for the Determination of Orlistat in Tablets. Molecules. 2017
Sep 10;22(9). pii: E1517. doi: 10.3390/molecules22091517. PubMed PMID: 28891958.

4: Xiao X, Liu H, Li X. Orlistat treatment induces apoptosis and arrests cell
cycle in HSC-3 oral cancer cells. Microb Pathog. 2017 Sep 4;112:15-19. doi:
10.1016/j.micpath.2017.09.001. [Epub ahead of print] PubMed PMID: 28882785.

5: Al-Tahami BAM, Al-Safi Ismail AA, Sanip Z, Yusoff Z, Shihabudin TMT, Singh
TSP, Rasool AHG. Metabolic and Inflammatory Changes with Orlistat and Sibutramine
Treatment in Obese Malaysian Subjects. J Nippon Med Sch. 2017;84(3):125-132. doi:
10.1272/jnms.84.125. PubMed PMID: 28724846.

6: Kujawska-Łuczak M, Musialik K, Szulińska M, Swora-Cwynar E, Kargulewicz A,
Grzymisławska M, Pupek-Musialik D, Bogdański P. The effect of orlistat versus
metformin on body composition and insulin resistance in obese premenopausal
women: 3-month randomized prospective open-label study. Arch Med Sci. 2017
Jun;13(4):725-731. doi: 10.5114/aoms.2016.62014. Epub 2016 Aug 29. PubMed PMID:
28721138; PubMed Central PMCID: PMC5510517.

7: Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M,
Bianconi V, Pirro M. Statistical vs clinical significance: A matter of debate for
orlistat treatment. Pharmacol Res. 2017 Oct;124:158-159. doi:
10.1016/j.phrs.2017.06.011. Epub 2017 Jun 23. PubMed PMID: 28652221.

8: Khazaei S, Hanis SM, Mansori K. Orlistat on plasma lipids and body weight
reduction: A really effective drug? Pharmacol Res. 2017 Sep;123:26. doi:
10.1016/j.phrs.2017.06.010. Epub 2017 Jun 23. PubMed PMID: 28648737.

9: Annamalai S, Mohanam L, Raja V, Dev A, Prabhu V. Antiobesity, antioxidant and
hepatoprotective effects of Diallyl trisulphide (DATS) alone or in combination
with Orlistat on HFD induced obese rats. Biomed Pharmacother. 2017 Sep;93:81-87.
doi: 10.1016/j.biopha.2017.06.035. Epub 2017 Jun 16. PubMed PMID: 28624425.

10: Souchek JJ, Davis AL, Hill TK, Holmes MB, Qi B, Singh PK, Kridel SJ, Mohs AM.
Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is
Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate
Cancer Cells. Mol Cancer Ther. 2017 Sep;16(9):1819-1830. doi:
10.1158/1535-7163.MCT-17-0013. Epub 2017 Jun 14. PubMed PMID: 28615298; PubMed
Central PMCID: PMC5598554.